Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Abstract Text:

Stephen H Petersdorf,Cathryn Rankin,David R Head,Howard R Terebelo,Cheryl L Willman,Stanley P Balcerzak,Anand B Karnad,Shaker R Dakhil,Frederick R Appelbaum,Stephen H Petersdorf,Cathryn Rankin,David R Head,Howard R Terebelo,Cheryl L Willman,Stanley P Balcerzak,Anand B Karnad,Shaker R Dakhil,Frederick R Appelbaum,Stephen H Petersdorf,Cathryn Rankin,David R Head,Howard R Terebelo,Cheryl L Willman,Stanley P Balcerzak,Anand B Karnad,Shaker R Dakhil,Frederick R Appelbaum,

Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100-200 mg/m(2)/day and an anthracycline. Such combinations produce complete response (CR) rates of 60-80% in patients with de novo AML. On the basis of a previous report, suggesting a higher CR rate using a regimen of standard daunomycin and cytarabine followed by 3 days of high-dose cytarabine (HDAC), 101 eligible patients received this regimen in a phase II trial. Sixty patients [59%, 95% confidence interval (CI) 49-69%] achieved a CR, and 10 patients died of infection during induction. Although cytogenetic risk group affected overall survival (P = 0.0016) and relapse-free survival (P = 0.0043), it had no impact on CR rate (P = 0.63). Patients received postremission therapy with repetitive courses of alternate day high-dose cytarabine; this was associated with considerable toxicity and the majority of patients could not receive all of the scheduled postremission therapy. The estimated median survival was 23 months (95% CI 15-34 months), and the estimated probability of surviving 5 years was 34% (95% CI 24-43%). The results of this intensive induction regimen were similar to that seen in previous trials and were not as promising as reported in the previous pilot study. Am. J. Hematol., 2007. (c) 2007 Wiley-Liss, Inc.

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Publishing Authors By Initials

SH Petersdorf,C Rankin,DR Head,HR Terebelo,CL Willman,SP Balcerzak,AB Karnad,SR Dakhil,FR Appelbaum,SH Petersdorf,C Rankin,DR Head,HR Terebelo,CL Willman,SP Balcerzak,AB Karnad,SR Dakhil,FR Appelbaum,SH Petersdorf,C Rankin,DR Head,HR Terebelo,CL Willman,SP Balcerzak,AB Karnad,SR Dakhil,FR Appelbaum,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of hematology

VOLUME: 82

Page Numbers: 1056-62

Journal Abbreviation: Am. J. Hematol.

ISSN: 0361-8609

DAY: 7

MONTH: Dec

YEAR: 2007

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7610369

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).

AFFILIATION: Division of Medical Oncology, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium, Seattle, Washington.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Hematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study SWOG-9500 Related Publications

• A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects.
• Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
• Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
• Agnogenic myeloid metaplasia: a case report.
• Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
• Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
• Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
• Coherent Spin Transport through a 350 Micron Thick Silicon Wafer.
• Commentary: the use of restraint and seclusion in correctional mental health.
• Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis.
• Development of autonomy: role of walking onset and its timing.
• Disclosure of information to potential subjects on research recruitment web sites.
• Ethics and forensic psychiatry: translating principles into practice.
• Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
• Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow.
• Hormone receptors in breast cancer.
• Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
• In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci.
• In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.
• Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
• Law & psychiatry: Death row delusions: when is a prisoner competent to be executed?
• Law & psychiatry: privilege in the federal courts: should there be a "dangerous patient exception"?
• Law & psychiatry: sex offenders in the community: are current approaches counterproductive?
• Molecular characterization of multidrug-resistant Streptococcus pneumoniae isolates in Korea. The Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group.
• Patients' competence to consent to treatment.
• Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).
• Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
• Retrolental fibroplasia; a disease of the eyes in premature infant; with report of a case.
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
• The voluntary patient--a psychiatrist's perspective.